Share on StockTwits

InterMune (NASDAQ:ITMN) EVP Paul D. Arata sold 2,382 shares of InterMune stock in a transaction dated Thursday, July 17th. The shares were sold at an average price of $41.00, for a total transaction of $97,662.00. Following the completion of the transaction, the executive vice president now directly owns 21,913 shares of the company’s stock, valued at approximately $898,433. The sale was disclosed in a filing with the SEC, which is available at this link.

Several analysts have recently commented on the stock. Analysts at Oppenheimer raised their price target on shares of InterMune from $42.00 to $50.00 in a research note on Monday, June 16th. They now have an “outperform” rating on the stock. Separately, analysts at JMP Securities raised their price target on shares of InterMune from $48.00 to $55.00 in a research note on Thursday, June 12th. They now have a “market outperform” rating on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of InterMune in a research note on Tuesday, June 10th. They now have a $51.00 price target on the stock, up previously from $45.00. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. InterMune presently has a consensus rating of “Buy” and an average target price of $43.46.

Shares of InterMune (NASDAQ:ITMN) traded up 3.86% on Monday, hitting $43.31. The stock had a trading volume of 1,873,284 shares. InterMune has a 52-week low of $10.95 and a 52-week high of $47.65. The stock’s 50-day moving average is $43.08 and its 200-day moving average is $30.97. The company’s market cap is $4.283 billion.

InterMune (NASDAQ:ITMN) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.59) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.62) by $0.03. The company had revenue of $30.30 million for the quarter, compared to the consensus estimate of $28.24 million. During the same quarter last year, the company posted ($0.64) earnings per share. InterMune’s revenue was up 188.6% compared to the same quarter last year. Analysts expect that InterMune will post $-2.32 EPS for the current fiscal year.

InterMune, Inc (NASDAQ:ITMN) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.